Brokerages expect Cassava Sciences Inc (NASDAQ:SAVA) to post earnings per share (EPS) of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Cassava Sciences’ earnings. Cassava Sciences also reported earnings per share of ($0.06) during the same quarter last year. The firm is scheduled to announce its next earnings results on Monday, August 10th.

On average, analysts expect that Cassava Sciences will report full-year earnings of ($0.26) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.90 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Cassava Sciences.

Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Several analysts recently commented on SAVA shares. Zacks Investment Research upgraded Cassava Sciences from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Saturday, May 9th. Maxim Group cut Cassava Sciences from a “buy” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price (up from $6.00) on shares of Cassava Sciences in a report on Friday, May 8th. Finally, ValuEngine upgraded Cassava Sciences from a “sell” rating to a “hold” rating in a report on Thursday, April 2nd.

Shares of Cassava Sciences stock traded down $5.99 on Friday, hitting $2.12. The stock had a trading volume of 47,175,674 shares, compared to its average volume of 2,834,354. The stock has a 50 day moving average of $6.17 and a 200 day moving average of $5.07. Cassava Sciences has a twelve month low of $1.02 and a twelve month high of $10.95. The firm has a market capitalization of $200.97 million, a P/E ratio of -9.22 and a beta of 3.28.

Institutional investors have recently bought and sold shares of the business. Jefferies Group LLC bought a new position in shares of Cassava Sciences during the 4th quarter worth approximately $364,000. Marshall Wace LLP bought a new position in shares of Cassava Sciences during the 4th quarter worth approximately $284,000. Jane Street Group LLC boosted its holdings in shares of Cassava Sciences by 23.4% during the 4th quarter. Jane Street Group LLC now owns 17,269 shares of the company’s stock worth $90,000 after buying an additional 3,279 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Cassava Sciences in the 4th quarter worth $79,000. Finally, Cetera Advisor Networks LLC bought a new position in shares of Cassava Sciences in the 4th quarter worth $109,000. Hedge funds and other institutional investors own 18.59% of the company’s stock.

About Cassava Sciences

Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

See Also: How to calculate compound interest

Get a free copy of the Zacks research report on Cassava Sciences (SAVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cassava Sciences (NASDAQ:SAVA)

Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.